Marker Therapeutics (MRKR) to Release Earnings on Monday

Marker Therapeutics (NASDAQ:MRKR) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $5.25 million for the quarter.

Marker Therapeutics Price Performance

MRKR stock opened at $1.24 on Monday. Marker Therapeutics has a twelve month low of $1.13 and a twelve month high of $5.99. The company’s 50 day moving average is $1.93 and its two-hundred day moving average is $2.87.

Insider Transactions at Marker Therapeutics

In other news, Director Steve Elms acquired 11,085 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now directly owns 325,370 shares in the company, valued at approximately $1,041,184. This represents a 3.53 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the transaction, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 14.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on MRKR shares. Canaccord Genuity Group started coverage on shares of Marker Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $8.00 target price on the stock. Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.